AR and adenocarcinoma: Briefly, all the organoids selected for the study were derived from patients with mCRPC with no evidence of neuroendocrine prostate cancer; harbor genomic loss of PTEN; and have adenocarcinoma histologic phenotypes ranging from more luminal to less luminal, variable expression of AR, and responsiveness to AR inhibition.